Takeda Signs Multi-Target Strategic Collaboration with Prometheus to Develop Targeted Therapies for Inflammatory Bowel Disease

Takeda Signs Multi-Target Strategic Collaboration with Prometheus to Develop Targeted Therapies for Inflammatory Bowel Disease

Shots:

  • Prometheus to receive up front, $420M as development, regulatory & commercial milestone with royalties on sales of each program and will be responsible for the identification and validation of three unique drug targets. Takeda to discover, develop & commercialize up to three targeted IBD therapeutics and companion diagnostics
  • The collaboration combines Prometheus’ bioinformatics analysis platform and CDx with Takeda’s expertise in gastroenterology and drug development to speed up the development and discovery of targeted IBD therapies And CDx
  • The targeted precision medicines are needed to deliver new, effective therapeutic options in inflammatory bowel disease

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Pharmaceutical Technology